Research programme: tuberculosis therapies - Prolexys
Alternative Names: Tuberculosis therapies research programme - ProlexysLatest Information Update: 16 Jul 2016
At a glance
- Originator Prolexys Pharmaceuticals
- Developer Imperial College of Science, Technology and Medicine
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Tuberculosis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Tuberculosis in United Kingdom
- 16 Jul 2016 No recent reports of development identified for preclinical development in Tuberculosis in USA
- 15 Aug 2005 Preclinical trials in Tuberculosis in United Kingdom (unspecified route)